2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·41 min sittenWhat happens if Americans now open their eyes… they see the valuation in the company ( extremely low right now) and they see the technology…? They start buying Circio shares… what happens to the price when dollars and foreign currency come in 💴 💴 ..?💥💥💥
·41 min sittenWhat are the expectations for Friday?
·6 min sittenHe's just asking, isn't he? I think you don't need to answer if you have a problem with it, mate.
·57 min sittenCIRCVEC IS NO LONGER A PROJECT – IT IS A PARALLEL INDUSTRIAL REVOLUTION! 🧬🚀🔥 Forget the idea that Circio is just "doing heart". What we are seeing unfold in Boston now, is a total offensive on four fronts simultaneously. While the market has blinked, Circio has built four parallel "value tracks" that each individually could have justified the company's entire value. Here is the raw strategic analysis of what is actually happening now: 1. THE HEART (Lead Indication): THE ENGINE THAT NEVER STOPS 🫀🛡️ This is the most mature track. With 40x higher expression and 80 % accuracy in heart cells, they have proven that circVec owns muscle tissue. Disease-model efficacy comes later in 2026. This is the foundation. 2. THE EYE (The Fast-Track): SURGICAL EFFICIENCY 👁️🎯 This track is accelerating at rocket speed. When you can show 50x improved expression and simultaneously reduce the dose by 90 % and still outperform regular AAV, then the phones from Big Pharma are ringing. The eye field is extremely dose-sensitive and commercially lucrative. This is "low hanging fruit" for a strategic transaction. 3. CNS (The Pharma Validation): FIRST BIG DEAL? 🧠🤝 This is perhaps the most strategic track right now. With a fully funded feasibility study together with a Top-5 Global Pharma player, the CNS program is the most likely path to the first massive licensing agreement. Validation from the biggest guys in the class is the ultimate seal of quality. 4. IN VIVO CAR-T (The Moonshot): MULTI-BILLION OPTIONALITY 🧬💰 The collaboration with LNP giant Acuitas (behind the Pfizer/BioNTech vaccine) is heavyweight. By combining circular RNA's long-lasting expression with targeted T-cell delivery, they are attacking a field where acquisitions recently have been in the multi-billion class (Orbital/BMS, Capstan/AbbVie). THE CONCLUSION: CIRCVEC IS AN EXPRESSION ENGINE FOR EVERYTHING! 🏛️⚖️ Circio has stopped being a "one-hit wonder". They are now building parallel angles of attack across: • Heart • Eye • CNS • Cell therapy (CAR-T / CAR-M) Status: We are no longer looking at a company waiting for one result. We are looking at a platform that becomes more valuable every day, because each success in one tissue validates the entire technology for the others. We are betting on the architects. We own the medicine of the future. ♟️🧱🍷
·1 t sitten · MuokattuReposting an old screenshot from April 14. An email correspondence between Erik Wiklund and me. (There were some naive unintelligent people in here who were skeptical about the credibility). 🐒 But it's legitimate! Anyways. Erik clearly writes that we should focus on May 15, when new data and a corresponding announcement will come. So I am almost 100% sure that we will see something solid tomorrow, as well as a stock exchange announcement 💰 I know he also mentions new data in "Poster", that is also preserved, but it is very technical and directly aimed at highly educated bio/lab personnel.
·1 t sittenExciting! How about the publication in Boston, versus the stock exchange closing in Norway? Is it the case that the rebound comes Monday, even if the news comes tomorrow as the stock exchange might be closed? We are six hours behind, after all. That means that 15:00 in Norway is 09:00 in Boston.- ·1 t sittenWhat do people think about what price it will be at in the coming months? Exciting to hear people's different opinions about it🙌🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·41 min sittenWhat happens if Americans now open their eyes… they see the valuation in the company ( extremely low right now) and they see the technology…? They start buying Circio shares… what happens to the price when dollars and foreign currency come in 💴 💴 ..?💥💥💥
- ·41 min sittenWhat are the expectations for Friday?·6 min sittenHe's just asking, isn't he? I think you don't need to answer if you have a problem with it, mate.
- ·57 min sittenCIRCVEC IS NO LONGER A PROJECT – IT IS A PARALLEL INDUSTRIAL REVOLUTION! 🧬🚀🔥 Forget the idea that Circio is just "doing heart". What we are seeing unfold in Boston now, is a total offensive on four fronts simultaneously. While the market has blinked, Circio has built four parallel "value tracks" that each individually could have justified the company's entire value. Here is the raw strategic analysis of what is actually happening now: 1. THE HEART (Lead Indication): THE ENGINE THAT NEVER STOPS 🫀🛡️ This is the most mature track. With 40x higher expression and 80 % accuracy in heart cells, they have proven that circVec owns muscle tissue. Disease-model efficacy comes later in 2026. This is the foundation. 2. THE EYE (The Fast-Track): SURGICAL EFFICIENCY 👁️🎯 This track is accelerating at rocket speed. When you can show 50x improved expression and simultaneously reduce the dose by 90 % and still outperform regular AAV, then the phones from Big Pharma are ringing. The eye field is extremely dose-sensitive and commercially lucrative. This is "low hanging fruit" for a strategic transaction. 3. CNS (The Pharma Validation): FIRST BIG DEAL? 🧠🤝 This is perhaps the most strategic track right now. With a fully funded feasibility study together with a Top-5 Global Pharma player, the CNS program is the most likely path to the first massive licensing agreement. Validation from the biggest guys in the class is the ultimate seal of quality. 4. IN VIVO CAR-T (The Moonshot): MULTI-BILLION OPTIONALITY 🧬💰 The collaboration with LNP giant Acuitas (behind the Pfizer/BioNTech vaccine) is heavyweight. By combining circular RNA's long-lasting expression with targeted T-cell delivery, they are attacking a field where acquisitions recently have been in the multi-billion class (Orbital/BMS, Capstan/AbbVie). THE CONCLUSION: CIRCVEC IS AN EXPRESSION ENGINE FOR EVERYTHING! 🏛️⚖️ Circio has stopped being a "one-hit wonder". They are now building parallel angles of attack across: • Heart • Eye • CNS • Cell therapy (CAR-T / CAR-M) Status: We are no longer looking at a company waiting for one result. We are looking at a platform that becomes more valuable every day, because each success in one tissue validates the entire technology for the others. We are betting on the architects. We own the medicine of the future. ♟️🧱🍷
- ·1 t sitten · MuokattuReposting an old screenshot from April 14. An email correspondence between Erik Wiklund and me. (There were some naive unintelligent people in here who were skeptical about the credibility). 🐒 But it's legitimate! Anyways. Erik clearly writes that we should focus on May 15, when new data and a corresponding announcement will come. So I am almost 100% sure that we will see something solid tomorrow, as well as a stock exchange announcement 💰 I know he also mentions new data in "Poster", that is also preserved, but it is very technical and directly aimed at highly educated bio/lab personnel.·1 t sittenExciting! How about the publication in Boston, versus the stock exchange closing in Norway? Is it the case that the rebound comes Monday, even if the news comes tomorrow as the stock exchange might be closed? We are six hours behind, after all. That means that 15:00 in Norway is 09:00 in Boston.
- ·1 t sittenWhat do people think about what price it will be at in the coming months? Exciting to hear people's different opinions about it🙌🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·41 min sittenWhat happens if Americans now open their eyes… they see the valuation in the company ( extremely low right now) and they see the technology…? They start buying Circio shares… what happens to the price when dollars and foreign currency come in 💴 💴 ..?💥💥💥
- ·41 min sittenWhat are the expectations for Friday?·6 min sittenHe's just asking, isn't he? I think you don't need to answer if you have a problem with it, mate.
- ·57 min sittenCIRCVEC IS NO LONGER A PROJECT – IT IS A PARALLEL INDUSTRIAL REVOLUTION! 🧬🚀🔥 Forget the idea that Circio is just "doing heart". What we are seeing unfold in Boston now, is a total offensive on four fronts simultaneously. While the market has blinked, Circio has built four parallel "value tracks" that each individually could have justified the company's entire value. Here is the raw strategic analysis of what is actually happening now: 1. THE HEART (Lead Indication): THE ENGINE THAT NEVER STOPS 🫀🛡️ This is the most mature track. With 40x higher expression and 80 % accuracy in heart cells, they have proven that circVec owns muscle tissue. Disease-model efficacy comes later in 2026. This is the foundation. 2. THE EYE (The Fast-Track): SURGICAL EFFICIENCY 👁️🎯 This track is accelerating at rocket speed. When you can show 50x improved expression and simultaneously reduce the dose by 90 % and still outperform regular AAV, then the phones from Big Pharma are ringing. The eye field is extremely dose-sensitive and commercially lucrative. This is "low hanging fruit" for a strategic transaction. 3. CNS (The Pharma Validation): FIRST BIG DEAL? 🧠🤝 This is perhaps the most strategic track right now. With a fully funded feasibility study together with a Top-5 Global Pharma player, the CNS program is the most likely path to the first massive licensing agreement. Validation from the biggest guys in the class is the ultimate seal of quality. 4. IN VIVO CAR-T (The Moonshot): MULTI-BILLION OPTIONALITY 🧬💰 The collaboration with LNP giant Acuitas (behind the Pfizer/BioNTech vaccine) is heavyweight. By combining circular RNA's long-lasting expression with targeted T-cell delivery, they are attacking a field where acquisitions recently have been in the multi-billion class (Orbital/BMS, Capstan/AbbVie). THE CONCLUSION: CIRCVEC IS AN EXPRESSION ENGINE FOR EVERYTHING! 🏛️⚖️ Circio has stopped being a "one-hit wonder". They are now building parallel angles of attack across: • Heart • Eye • CNS • Cell therapy (CAR-T / CAR-M) Status: We are no longer looking at a company waiting for one result. We are looking at a platform that becomes more valuable every day, because each success in one tissue validates the entire technology for the others. We are betting on the architects. We own the medicine of the future. ♟️🧱🍷
- ·1 t sitten · MuokattuReposting an old screenshot from April 14. An email correspondence between Erik Wiklund and me. (There were some naive unintelligent people in here who were skeptical about the credibility). 🐒 But it's legitimate! Anyways. Erik clearly writes that we should focus on May 15, when new data and a corresponding announcement will come. So I am almost 100% sure that we will see something solid tomorrow, as well as a stock exchange announcement 💰 I know he also mentions new data in "Poster", that is also preserved, but it is very technical and directly aimed at highly educated bio/lab personnel.·1 t sittenExciting! How about the publication in Boston, versus the stock exchange closing in Norway? Is it the case that the rebound comes Monday, even if the news comes tomorrow as the stock exchange might be closed? We are six hours behind, after all. That means that 15:00 in Norway is 09:00 in Boston.
- ·1 t sittenWhat do people think about what price it will be at in the coming months? Exciting to hear people's different opinions about it🙌🏼
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt